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Abstract
The two unrelated miRNAs, miR-143 and miR-145, co-expressed from the miR-143/145 cluster 
have been proposed to act as tumor suppressors in human cancer and therapeutic benefits of 
delivering miR-143 and miR-145 to tumors have been reported. In contrast, we found that tumor-
specific deletion of miR-143/145 in an autochthonous mouse model of lung adenocarcinoma did 
not affect tumor development. This was consistent with the lack of endogenous miR-143/145 
expression in normal and transformed lung epithelium. Surprisingly, miR-143/145 in the tumor 
microenvironment dramatically promoted tumor growth by stimulating the proliferation of 
endothelial cells. Loss of miR-143/145 in vivo led to derepression of the miR-145 target Camk1d, 
an inhibitory kinase, which when overexpressed prevents mitotic entry of endothelial cells. As a 
consequence, tumors in miR-143/145-deficient animals exhibited diminished neoangiogenesis, 
increased apoptosis and their expansion was limited by the tumor’s ability to co-opt the alveolar 
vasculature. These findings demonstrate that stromal miR-143/145 promotes tumorigenesis and 
cautions against the use of these miRNAs as agents in cancer therapeutics.
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INTRODUCTION
MicroRNAs (miRNAs) influence diverse cellular processes through their ability to modulate 
gene expression programs and dysregulation of miRNA expression has been linked to 
various disease states, including cancer (1, 2). In particular, miRNA profiling of tumors 
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demonstrated that miR-143 and miR-145, two unrelated miRNAs co-expressed from the 
miR-143/145 cluster, show reduced expression compared to adjacent normal tissue in a 
variety of human tumors of epithelial origin (3-8). Functional studies have revealed that 
ectopic expression of these miRNAs promotes apoptosis, inhibits proliferation, and limits 
the tumor-forming capacity of diverse tumor cell types, suggesting a potential role for 
miR-143 and miR-145 in cell autonomous tumor suppression (9-12). Additionally, several 
reports indicate a therapeutic benefit of miR-143 or miR-145 delivery in subcutaneous and 
orthotopic models of pancreatic cancer and in colorectal carcinoma xenografts (13-15). In 
these overexpression studies, the tumor suppressive functions of miR-143 appear to be 
mediated through its ability to target the 3′ untranslated regions (3′UTRs) of several 
oncogenes, including K-ras and Erk5, whereas miR-145 represses the expression of Myc, 
Yes, Fascin, and Stat, among others (9, 11, 12, 16-18). Despite the existence of several 
independently generated miR-143/145 knockout mouse model, however, the tumor 
suppressive functions of endogenous miR-143 and miR-145 have not been tested in vivo 
(19-22).
Recent reports revealing the role of endogenous miR-143/145 in intestinal epithelial 
regeneration, pulmonary fibrosis, and skin wound healing have challenged the cell 
autonomous model for miR-143/145 function (23-25). These studies show that miR-143 and 
miR-145 are not expressed in cells of epithelial origin. Instead, upregulation of miR-143 and 
miR-145 in stress-activated myofibroblasts stimulates epithelial regeneration via paracrine 
mechanisms. To address the possibility that expression of the miR-143/145 cluster in the 
stroma may play an analogous, stimulatory role during the process of tumorigenesis, we 
have utilized the KrasLSL-G12D/+ (K) autochthonous mouse model of lung adenocarcinoma, 
a type of cancer, in which downregulation of the miR-143/145 cluster has been reported. 
Tumorigenesis in the K model is initiated in a subset of adult lung epithelial cells via 
intratracheal infection with viral Cre recombinase, which activates mutant KrasG12D from 
the endogenous locus (26), thus preserving its 3′UTR and the potential for regulatory 
interactions with miRNAs, including miR-143. Concomitant deletion of p53 in 
KrasLSL-G12D/+;p53F/F (KP) mice promotes the development of lung adenocarcinomas that 
closely recapitulate the pathophysiological features of the human disease (27).
Here, we demonstrate that the miR-143/145 cluster is not expressed in normal and 
transformed lung epithelium and does not play a cell-autonomous tumor suppressor role in 
lung tumorigenesis. Instead, we find that stromal miR-143/145 promotes tumor development 
in K mice. We report expression of these miRNAs in a subset of lung endothelial cells and 
identify a novel role for the miR-143/145 cluster in supporting tumor neoangiogenesis. This 
study highlights the utility of using autochthonous mouse models of cancer to understand the 
complex involvement of tumor stroma in cancer development.
RESULTS
Dissecting the proposed tumor suppressive functions of the miR-143/145 cluster using 
genetically engineered mouse models
To investigate the proposed tumor suppressive functions of miR-143 and miR-145 in vivo, 
we generated a conditional knockout for the miR-143/145 cluster (Supplementary Fig. S1A, 
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B). miR-143/145-floxed (F) and null (−) alleles were obtained by crossing founders to FlpO 
or Deleter Cre transgenic animals, respectively (Supplementary Fig. S1A, C) (28, 29). Loss 
of mature miRNA expression in these animals was confirmed by northern blotting and 
miRNA Taqman assay (Supplementary Fig. S1D, E). As previously reported, mice lacking 
miR-143 and miR-145 were viable, born at Mendelian ratios, and exhibited predominantly 
age-related, smooth muscle-specific phenotypes, including loss of elasticity in the aorta, 
megacolon manifestation, and male infertility (Supplementary Fig. S1F, G) (19-22). Studies 
on ageing cohorts of littermate mice revealed that loss of expression of miR-143/145 alone 
or in the context of a sensitized p53 heterozygous background did not predispose to tumor 
development (Supplementary Fig. S1H-J) (30). Moreover, primary mouse embryonic 
fibroblasts (MEFs) lacking miR-143/145 did not exhibit increased proliferation rates 
(Supplementary Fig. 2SA, B). Finally, loss of these miRNAs failed to cooperate with 
oncogenic H-ras, c-Myc, or E1A in promoting oncogenic transformation of MEFs, assayed 
by the ability to form colonies at low densities, loss of contact inhibition, and anchorage-
independent growth (data not shown). Together, these studies indicated that miR-143 and 
miR-145 did not appear to act as classical tumor suppressor genes.
Investigating the role of the miR-143/145 cluster in lung adenocarcinoma
Next, we investigated the role of the miR-143/145 cluster in the KP mouse model of lung 
adenocarcinoma, a type of cancer, in which tumor suppressor activities of these miRNAs 
have been reported. Consistent with the human data (8), we found by quantitative RT-PCR 
(qRT-PCR) that miR-143 and miR-145 levels were significantly reduced in tumor tissue and 
tumor-derived cell lines compared to normal lung (Fig. 1A, B). To test directly whether loss 
of miR-143 and miR-145 affected tumorigenesis, we infected cohorts of 
KP;miR-143/145F/F, F/+ and +/+ mice with Cre recombinase to initiate lung tumors and 
induce concomitant tumor-specific deletion of miR-143 and miR-145 (Fig. 1C). Contrary to 
expectations, we found that mutation of the miR-143/145 cluster in KP tumors did not affect 
tumor burden at 8 and 10 weeks post tumor initiation and did not have a significant impact 
on overall survival (Fig. 1D, E). We concluded that loss of endogenous miR-143 and 
miR-145 expression did not promote lung adenocarcinoma development.
Given the apparent controversy with published data, we reasoned that these miRNAs may 
exhibit tumor suppressive activities in the context of forced overexpression through their 
ability to target critical oncogenes, as previously reported. To test this, we cloned miR-143 
and miR-145 into the 3′UTR of mCherry in the pTMMPC lentiviral vector, which drives 
doxycycline-regulated induction of mCherry and concomitant miRNA expression (Fig. 1F) 
(31). This bifunctional pTMMPC vector also constitutively expresses Cre recombinase, 
required to initiate tumorigenesis in this model. We generated pTMMPC-miR-143 and 
pTMMPC-miR-145 lentivirus and infected cohorts of KP;CCSP-rtTA+ or control CCSP-
rtTA− mice (Fig.1F) (32). All mice were fed doxycycline diet at tumor initiation. At 12 
weeks post tumor initiation, we confirmed transgene expression by mCherry fluorescence in 
whole lungs and qRT-PCR of individual tumors (Fig. 1G, H). Low levels of miR-143 and 
miR-145 observed in two of the KP;CCSP-rtTA+ tumors likely reflected repressive features 
of the lentiviral integration sites or were a consequence of loss of activity from the CCSP 
promoter. Despite evidence that the majority of KP;CCSP-rtTA+ tumors expressed high 
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levels of either miR-143 or miR-145, there was no significant difference in overall tumor 
burden between rtTA+ and rtTA− cohorts, indicating that forced miRNA expression did not 
influence tumor development in this model (Fig. 1I). Similarly, exogenous introduction of 
miR-143 and miR-145, individually or in combination, did not affect the viability or alter 
the proliferation rates in KP cell lines (Supplementary Fig. S2C, D). Finally, expression of 
miR-143/145 at endogenous levels did not appear to target K-ras or RREB1, two previously 
proposed targets relevant to the tumor suppressive functions of miR-143/145 
(Supplementary Fig. S2E, F) (11). In summary, these data did not support previous studies, 
which have reported significant cell autonomous tumor suppressive activities of miR-143 
and miR-145 in tumor cell lines in vitro and in vivo.
Expression of miR-143/145 in tumor stroma promotes lung tumorigenesis
Since the miR-143/145 cluster has been shown to promote epithelial regeneration through a 
non-cell autonomous mechanism, we examined the role of stromal miR-143 and miR-145 in 
the context of lung cancer development (20). To this end, we initiated tumorigenesis using 
adenoviral Cre recombinase in cohorts of K;miR-143/145+/+, F/F, and −/− mice and assayed 
tumor burden at 12 weeks (Fig. 2A). Consistent with the data shown in Fig. 1D, the tumor 
burden of K;miR-143/145F/F animals, which have tumor-specific miRNA deletion, was 
indistinguishable from control animals (Fig. 2A-C). Surprisingly, however, histological 
analysis of K;miR-143/145−/− animals, which have organism-wide deletion of the cluster, 
revealed a dramatically reduced tumor burden (Fig. 2A). There was a two-fold decrease in 
tumor area and a three-fold reduction in the number of tumors per section (Fig. 2B, C). 
These data indicated that systemic miR-143/145 expression played an unanticipated role in 
promoting tumor development.
Similar reduction of tumor burden in the lung was observed when a 
KP;miR-143/145+/+;EGFP+ cell line was introduced via tail vein injection (t.v.i.) in 
congenic miR-143/145+/+ or miR-143/145−/− animals (Fig. 2D). In this transplant model, 
tumor cells preferentially colonize the lungs, where they develop aggressive lung 
adenocarcinomas with short latency. Histological analysis at 4 weeks post t.v.i. revealed that 
formation of tumor nodules in the lungs of miR-143/145-deficient animals was significantly 
impaired relative to wild-type, littermate controls (Fig. 2D, E). Time-course experiments, 
combined with immunohistochemistry (IHC) detection of tumor cells using the EGFP 
marker, indicated that absence of miR-143/145 did not affect the colonization of the lungs 
(quantified as tumor nodules/section) and only moderately limited the initial expansion of 
the tumor nodules (quantified by number of cells/tumor nodule) (Fig. 2F). Surprisingly, even 
at late timepoints, when the tumor burden was significantly lower in knockout animals, there 
was no apparent difference in proliferation rates (Fig. 2G). Instead, there was a small but 
significant increase in the incidence of apoptosis in tumors developing in miR-143/145-
deficient animals, indicating that systemic loss of these miRNAs imposed stress that limited 
tumor expansion (Fig. 2H).
Together, these experiments provided genetic evidence that systemic expression of miR-143 
and/or miR-145 supported tumor cell survival in the lung through a non-cell autonomous 
mechanism, pointing to a potential role of these miRNAs in the tumor microenvironment. 
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This was specific to the lung as the rate of subcutaneous growth of the 
KP;miR-143/145+/+;EGFP+ cell line was indistinguishable between miR-143/145-proficient 
and –deficient animals, indicating functional differences between the stroma of the lung and 
the tumor microenvironment at subcutaneous transplant sites (Supplementary Fig. S3A, B).
In an effort to elucidate the underlying mechanism, we performed IHC analysis of the 
infiltration pattern and morphological characteristics of tumor-associated cell types but 
failed to detect significant miRNA-dependent differences (Supplementary Fig. S4A, B). In 
addition, immunofluorescence (IF) analysis of lung tumors showed no apparent differences 
in IGF signaling, assayed by the pattern and intensity of pIGFR-Y116 staining, contrasting a 
previously proposed model for the contribution of fibroblast-derived miR-143/145 
expression to epithelial regeneration in the colon (Supplementary Fig. S4C) (20). We 
hypothesized that miR-143 and miR-145 promoted lung tumor development through a novel 
mechanism.
Rare endothelial cells in the lung stroma express miR-143/145
To identify the stromal compartments that expressed miR-143/145, we performed miRNA 
fluorescence in situ hybridization (FISH) in sections of normal and tumor-bearing lungs. As 
a positive control, we confirmed that miR-143 and miR-145 were abundant in the 
submucosa and muscularis mucosa layers in the colon and found them highly expressed in 
the smooth muscle lining of bronchioles and arteries in the lung (Supplementary Fig. S5A) 
(28, 29). The lung epithelium appeared largely devoid of miRNA signal with the exception 
of rare miRNA positive cells found in the alveolar walls as well as scattered throughout KP 
tumors (Fig. 3A). The staining was specific to miR-145 as there was no signal in sections 
where the probes were omitted or in miR-143/145-deficient tissues (Fig. 3A).
To determine the identity of the miR-143/145-expressing cells, we performed fluorescence-
activated cell sorting (FACS) of dissociated lungs using cell surface markers to isolate the 
prevalent cell types. This strategy allowed us to evaluate miRNA levels in endothelial cells 
(CD31+, also known as PECAM1), immune cells (CD45+, also known as PTPRC), epithelial 
cells (Epcam+), and in the triple-negative fraction (CD31-CD45−Epcam−), thought to 
include smooth muscle cells, fibroblasts, pericytes, and activated neutrophils 
(Supplementary Fig. S5B, C). Taqman probes specific to the mature miR-143 and miR-145 
sequences revealed that, relative to total lung, this cluster was depleted in immune and 
epithelial cells and enriched in endothelial cells and the triple-negative fraction (Fig. 3B). 
miRNA-FISH detection of miR-145 in normal lung and lung tumors showed close 
association of miRNA-positive cells with the vasculature, marked by fluorescently-labeled 
lectin, further pointing to endothelial identity (Fig. 3C). We concluded that the epithelial 
compartment of the lung was devoid of miR-143 and miR-145 expression, providing an 
explanation for the lack of tumor suppressive activities of these miRNAs during lung 
adenocarcinoma development. Instead, we observed that endothelial cells in vivo are 
enriched for the miR-143/145 cluster.
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Reduced endothelial proliferation in miR-143/145-deficient mice
To elucidate the pathway that promoted tumor development downstream of miR-143/145, 
we performed global gene expression analysis in sorted epithelial (Epcam+), endothelial 
(CD31+) and triple-negative (CD31−CD45−Epcam−) cell populations, isolated 18 weeks 
post tumor initiation from three K;miR-143/145−/− mice and three K;miR-143/145+/+ 
littermate controls (Fig. 4A). Unsupervised clustering of RNA sequencing (RNA-seq) data 
segregated the three fractions as distinct populations (Fig. 4B). Independent Component 
Analysis (ICA) elucidated in an unbiased manner five statistically significant signatures 
within the dataset, establishing the level of purity and specificity of each sorted fraction 
(Supplementary Fig. S5D, E; Supplementary Table 1) (Bhutkar, A. et al, in preparation).
Next, we investigated the differences between miR-143/145-deficient and – proficient 
samples. ICA did not detect biologically relevant differences between wild-type and null 
epithelial and triple-negative populations but highlighted one statistically significant 
signature that distinguished miR-143/145−/− endothelial samples from controls (Signature 
End4, p<0.05, Fig. 4C, Supplementary Table 2). GSEA of the top ranked genes within this 
signature identified gene sets related to the mitotic cell cycle and revealed a strong depletion 
of mitotic genes in miR-143/145-deficient endothelial cells compared to wild-type controls 
(Fig. 4D). This finding was supported by pair-wise comparison of differentially expressed 
genes between knockout and wild-type endothelial samples, which showed that 17 out of the 
19 significantly repressed genes (FC[KO/WT]<0.67, p<0.05) were either mediators of 
mitosis or factors, whose levels peak in M-phase of the cell cycle (Fig. 4E and 
Supplementary Table 3 and 4). Genes showing consistently reduced levels in miR-143/145-
deficient endothelial samples compared to controls included three essential components of 
the mitotic checkpoint complex (Bub1, Bub1b, and Cdc20) as well as the well-established 
marker of proliferation Ki67 (Fig. 4F and Supplementary Table 3). Finally, immunoblot 
analysis of CD31+ endothelial cells isolated from tumor-bearing lungs of knockout animals 
showed diminished levels of the mitotic marker, phosphorylated histone H3 (pHH3-Ser10), 
compared to wild-type controls (Fig. 4G). Collectively, these data pointed to a mitotic defect 
in the endothelium of tumor-bearing miR-143/145-deficient lungs and suggested that loss of 
these miRNAs may impair the process of tumor angiogenesis.
The miR-143/145 cluster promotes tumor neoangiogenesis
Based on the reduction of the mitotic index, we expected that the tumor vascularization in 
K;miR-143/145−/− animals would be grossly impaired. However, quantification of the 
vascular area using the endothelial marker CD31 or fluorescently labeled lectin did not 
reveal a miR-143/145-dependent difference (Fig. 5A-C). Instead, we noted honeycomb 
structures in K;miR-143/145−/− tumors, reminiscent of the normal alveolar architecture, 
whereas tumor vessels in K;miR-143/145+/+ mice appeared short and stubby (Fig. 5A, B, 
arrows). This pattern suggested that tumors in null animals may have expanded by co-opting 
the normal lung vasculature, rather than by sprouting new vessels (33). In agreement with 
this model, we observed reduced numbers of Dll4-positive tip cells, a marker of vessel 
sprouting and active neoangiogenesis in K;miR-143/145−/− animals compared to control 
K;miR-143/145+/+ mice (Fig. 5D, E; 4.4-fold reduction) (34). We propose that impaired 
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activation of the angiogenic switch is the mechanism by which loss of miR-143/145 
expression inhibits tumor development.
Identification of relevant miRNA targets
Finally, we addressed the mechanism by which miR-143/145 regulated mitotic entry in 
endothelial cells. To identify biologically relevant miRNA targets, we analyzed the 
endothelial cells expression data focusing on conserved miR-143 and miR-145 targets 
predicted by Targetscan (35). Using several independent approaches, we did not detect 
global patterns that distinguished between wild-type and null endothelial samples (Fig. 6A, 
B and data not shown). However, at the gene level, we noted that the conserved miR-145 
target, Camk1d (Ca2+/calmodulin kinase 1d) was consistently upregulated in null samples 
compared to wild-type controls (Fig. 6C). Camk1d showed a 36% increase in expression in 
null samples relative to wild-type controls (p<0.05, Fig. 6D and Supplementary Table 3). 
Camk1d is a poorly characterized member of the Ca2+/calmodulin-dependent family of 
serine/threonine kinases, which have been implicated in the regulation of a wide range of 
cellular processes, including control of cellular proliferation and angiogenesis (36, 37). 
Notably, the 3′UTR of Camk1d contains two conserved miR-145 sites. We confirmed that 
Camk1d is a direct target of miR-145 using two independent approaches. Loss of 
endogenous miR-145 led to derepression of luciferase activity when the luciferase gene was 
cloned prior to the 3′UTR of Camk1d (Fig. 6E, F). In addition, site-directed mutagenesis of 
one or both miR-145 sites within the 3′UTR of Camk1d abolished repression of luciferase 
activity (Fig. 6E, G).
Finally, we tested whether increased expression of Camk1d affected mitotic progression in 
endothelial cells using lentiviral delivery of Camk1d in human umbilical vein endothelial 
cells (HUVECs). Camk1d overexpression led to diminished levels of pHH3-Ser10, 
recapitulating the in vivo phenotype of miR-143/145 deficiency (Fig. 6H). In addition, 
ectopic Camk1d dramatically impaired the ability of HUVECs to form capillary-like 
structures in a tube formation assay, an approach used to model the process of angiogenesis 
in vitro (Fig. 6I). Together, these results pointed to Camk1d as a potential mediator of the 
mitotic defects observed in miR-143/145-deficient endothelial cells. However, we cannot 
exclude that derepression of additional miR-143 and miR-145 targets may contribute to the 
observed phenotype.
DISCUSSION
Our in vivo analysis of miR-143/145 function in a mouse model of lung adenocarcinoma 
provides genetic evidence that stromal miR-143 and miR-145 play a role in promoting 
tumor development. This conclusion contrasts with a large number of previous reports, 
which have implicated these miRNAs in cell autonomous tumor suppression. The basis for 
the majority of these studies has been the observation that expression of the miR-143/145 
cluster is reduced in tumor tissues and tumor-derived cell lines compared to normal samples. 
Here, we provide evidence that the reported differential expression is not likely due to 
effects in the transformed cells per se but reflects the cell-type specificity of miR-143/145 
expression and can be attributed to the cellular composition of the samples tested. Using two 
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independent approaches in vivo, we demonstrate low levels of mature miR-143 and miR-145 
in epithelial cells and higher levels in smooth muscle cells, fibroblasts, and endothelial cells. 
These data suggest that the apparent reduction of miR-143/145 expression in tumors can be 
explained by their largely epithelial composition (20). These findings also shed light on why 
tumor-specific depletion of these miRNAs did not affect tumorigenesis in the K and KP 
models.
In addition to clarifying the cell type specificity of expression, several lines of evidence 
presented here challenge the view of miR-143 and miR-145 as universal tumor suppressors. 
We observed lack of predisposition of miR-143/145 knockout mice to tumor development, 
no effect of miR-143/145 loss on the proliferation rate or transformation capacity in MEFs, 
and no tumor suppressive consequences of miR-143 and miR-145 overexpression in tumor 
cells in vitro and in vivo. Collectively, these data suggest that the previously reported tumor 
suppressive activities of miR-143 and miR-145 are likely to be context-specific.
Instead, we present evidence that stromal miR-143/145 plays a pro-tumorigenic role in vivo 
and promotes lung adenocarcinoma progression. This was specific to the lung tumor 
microenvironment but not at sites of subcutaneous transplants, revealing organ-specific 
requirements. The unexpected ability of miR-143/145 to support tumor growth is consistent 
with a previous study, which examined the role of the cluster in the context of epithelial 
regeneration following colonic injury (20). Our analysis further revealed a novel lung-
specific mechanism by which stromal miR-143/145 supports tumor growth through the 
stimulation of mitotic progression of endothelial cells. We propose that a failure to activate 
the angiogenic switch in miR-143/145-deficient mice leads to increased apoptotic rates and 
limited tumor expansion. A similar function in promoting pathological angiogenesis has 
previously been described for a number of miRNAs, including miR-132 and miR-93 (38, 
39).
Interestingly, deletion of the miR-143/145 cluster did not lead to a global derepression of 
miR-143 or miR-145 targets in endothelial cells. Of note, miR-143 has two additional family 
members expressed in the mouse genome, miR-1721 and miR-4770, which may provide 
redundancy in the regulation of miR-143 targets. In addition, we imagine that the small 
changes in gene expression induced by miRNA deficiency, while physiologically relevant, 
may be difficult to detect in vivo. Alternatively, lack of an apparent miRNA signature may 
be explained by the observation that only a subset of endothelial cells express miR-143/145 
and thus expression analysis of bulk endothelial populations may not allow for target 
identification. Detection of miR-143/145 expression in a small subset of endothelial cells 
could be explained by transcriptional control by factors such as KLF2, a known mediator of 
endothelial activation (40) or by their transfer from smooth muscle cells to endothelial cells, 
as recently shown in vitro (41). In the context of these in vivo limitations, we identified only 
one miR-145 target, Camk1d as significantly derepressed in the miR-143/145-deficient 
endothelium. The targets of Camk1d in mammalian cells have not been identified and it 
remains to be determined how Camk1d overexpression impairs tumor neoangiogenesis in 
vivo. Interestingly, a recent study in S. pombe reported a role for the yeast homolog of this 
kinase in the phosphorylation and inhibition of Cdc25 (42). This provides a potential 
explanation for the mitotic defect observed in miR-143/145-deficient endothelial cells, as in 
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mammalian cells the Cdc25c phosphatase mediates the critical step that drives progression 
into mitosis. In support of this model, exogenous overexpression of Camk1d in HUVECs 
resulted in defective mitosis and reduced tube formation in an angiogenesis assay in vitro. 
These findings implicate miR-145 as a regulator of neoangiogenesis at least in part through 
the repression of a kinase in control of a key regulatory signal transduction pathway.
In summary, this study elucidates a non cell-autonomous requirement for miR-143/145 
expression in lung cancer development and identifies a novel role for these miRNAs as key 
modulators of endothelial function in cancer biology. This work highlights the power of 
using defined genetic systems and autochthonous mouse models of cancer to dissect the in 
vivo contribution of stroma-specific factors to tumor progression. The model presented here 
has general implications for the role of cell-type specific miRNAs in influencing critical 
steps in tumorigenesis and the potential to harness these regulatory networks for therapeutic 
purposes.
MATERIALS AND METHODS
Mouse strains and treatments
All animal work was conducted in accordance with a protocol approved by the MIT 
Committee on Animal Care. The miR-143/145 targeting construct was electroporated into 
V6.5 ES cells. Correctly targeted clones were used to generate miR-143/145targ/+ mice by 
tetraploid complementation and mice were back-crossed to pure C57BL/6 background using 
Taconic Speed Congenics. KrasLSL-G12D/+, p53F/F, and CCSP-rtTA mice have previously 
been described (26, 27, 32).
Lung tumorigenesis was initiated as described in (43) by intratracheal infection of mice with 
Cre-expressing adenovirus (Ad5-CMV-Cre, University of Iowa Gene Transfer Core) or with 
Cre- and miR-143- or miR-145-expressing pTMMPC lentiviruses (31).
For histological analyses, tissues were fixed in 4% formalin, embedded in paraffin, and 
sections were stained with hematoxylin and eosin (H&E). Tumor area was determined using 
NIS-Elements imaging software.
For IF and miRNA-FISH analysis, mice, untreated or injected intravenously with an Alexa 
Fluor 568-conjugated Isolectin IB4 conjugate (100 μg in 100 μl, Life Technologies) for 10 
minutes were perfused with PBS, followed by perfusion with 2% paraformaldehyde (PFA). 
After an overnight fixation in 4% PFA at 4°C, lung and control organs were placed in 30% 
sucrose overnight at 4°C with shaking. Lungs were inflated with an OCT:PBS (1:1) solution 
and embedded in OCT (Tissue-Tek). Frozen sections (10 μm thick) were cut on a CryoStar 
NX70 (Thermo Scientific).
Cell lines and treatments
We isolated primary MEFs from littermate E13.5 embryos in our laboratory and maintained 
the cells in DMEM supplemented with 15% FBS, pen/strep, L-glutamine, non-essential 
amino acids, and β-mercaptoethanol. miR-143/145F/F;CreER and control MEFs were 
isolated October 2010; miR-143/145F/F;KrasFSF-G12D/+;CreER and control MEFs were 
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isolated August 2011. All MEFs were authenticated by genotyping and RNA expression 
analysis.
We derived the KrasG12D/+;p53−/− cell line (LG1233) in our laboratory in May 2012 from 
individual tumors dissected from KrasLSL-G12D/+;p53F/F C57BL/6 mice at 10 week after 
intratracheal administration of Ad5-CMV-Cre. The cell lines used have not been 
authenticated. The cells were transduced with a lentivirus co-expressing GFP and luciferase 
and selected for GFP expression by FACS. Following passaging in C57BL/6J 
immunocompetent mice, individual lung tumors were re-isolated. The cells with highest 
GFP expression levels were selected by FACS (LG1233S1P1) and used for intravenous and 
subcutaneous transplantation by injecting 105 cells in 100 μl PBS.
Primary miRNA sequences cloned downstream of the tetracycline response element (TRE) 
in the pSLIK lentiviral expression system (44) were introduced in KrasG12D/+;p53−/− cell 
lines. Cells were selected with hygromycin and treated with 1 μg/ml doxycycline to induce 
miRNA expression.
HUVEC cells (ATCC CRL-1730, authenticated by short tandem repeat analysis by ATCC 
and not re-authenticated by our lab) were serum starved for 16 hours. 2×105 cells were 
seeded on growth-factor reduced Matrigel (Corning)-coated wells, and tube formation was 
imaged by brightfield microscopy at indicated time-points.
miRNA Fluorescence in situ hybridization (miRNA FISH)
Cryostat sections were dried and fixed in 4% PFA for 10 minutes. Sections were blocked in 
Hybridization buffer (50% formamide, 5xSSC, 1xDenhards, 500 μg/ml yeast tRNA in H20) 
for 30 minutes at 54°C and incubated with FITC-labeled miR-143 or miR-145-specific 
miRCURY LNA Detection Probes (Exiqon, 38515-04 and 38517-04) diluted in 
Hybridization buffer for 2 hours at 50°C in shaking waterbath. Following three washes with 
0.1xSSC at 58°C and one wash with 2xSSC at RT, sections were incubated with 3% H2O2 
for 10 minutes and washed three times for 3 minutes in TN buffer (0.1M Tris-HCl, pH 7.5; 
0.15M NaCl). The FITC label was amplified by blocking for 30 minutes with Blocking 
buffer (2 mg/ml BSA; 2% sheep serum in TN buffer) and incubating for 30 minutes with 
HRP-conjugated anti-FITC antibody (Dako, P5100) diluted in Blocking buffer, followed by 
three 5-minute washes with Washing buffer (TN with 0.3% Triton X-100). Signal 
amplification was performed by incubating slides with FITC-tyramide (TSA-Fluorescien 
System, Perkin Elmer) for 10 minutes. Three 5-minute washes with TNT were performed 
and the slides were mounted in ProLong Gold Mounting Medium (Invitrogen). Images were 
visualized under a Nikon microscope and processed in Photoshop.
Fluorescence Activated Cell Sorting (FACS)
Lungs were minced using a razor blade and incubated in dissociation solution containing 
DNAse (40 U/ ml, Roche) and Collagenase IV (1,000 U/ml, Worthington) rotating at 37°C 
for 1 hour. Following red blood cell lysis, cells were blocked for 15 minutes at 4°C and 
stained with the following primary antibodies for 25 minutes at 4°C: CD31-APC (BD 
Pharmingen), CD45-PE-Cy7 (BD Pharmingen), Epcam-FITC (Biolegend). DAPI 
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(Invitrogen) was used to exclude dead cells. FACS sorting was carried out on a BD 
FACSAria (BD Biosciences) prior to RNA sequencing, qRT-PCR, or immunoblot analyses.
RNA isolation and quantitative RT-PCR
RNA was isolated with the RNeasy Mini Kit (Qiagen), reverse transcribed using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and used for qPCR using 
KAPA SYBR Fast Master Mix (Kapa Biosystems, KK4604). The following primers were 
used: GAPDH F- agcttgtcatcaacgggaag, R- tttgatgttagtggggtctcg; pri-miR-143 F- 
gaagatgtcctgcagccgtca, R- tctagggacaacctatctagtcc; pri-miR-145 F- tggatctgtctccctccca, R- 
ttacctccgacgaaccgcctcc; mCherry F- cacctacaaggccaagaagc, R- tggtgtagtcctcgttgtgg; Kras F- 
ggtggttggagctggtggcg, R- cctgtaggagtcctctatcgtagggt; RREB1 F- cgaggactgctgcgccacaat, R- 
acaccaggcctgagagattcga; CD31 F- cggtgttcagcgagatcc, R- actcgacaggatggaaatcac; CD45 F- 
catccatcctcgtccactg, R- attgaacaaggcacagaacaac; SPC F- ccactggcatcgttgtgtat, R- 
gccatcttcatgatgtagcagt; SMA F- ctctcttccagccatctttcat, R- tataggtggtttcgtggatgc. Expression 
levels were calculated relative to GAPDH and normalized to control samples.
Analysis of mature miRNA levels was performed by isolating RNA using the miRNeasy 
Mini Kit (Qiagen) and performing miR-143 and miR-145-specific Taqman MicroRNA 
Assays (Life Technologies) using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems) and Taqman Fast Universal PCR Master Mix (Life Technologies). 
Expression levels were calculated relative to U6 snRNA (Life Technologies).
Immunoblotting
Cells were collected, counted and lysed in 2x Laemmli buffer. Samples were heated to 95°C 
for 7 minutes and passed through an insulin syringe. Immunoblotting was performed using 
the following antibodies: Camk1d (Cell Signaling, 3365), pHH3 (Cell Signaling, 9701), 
Hsp90 (BD Biosciences, 610418).
Immunofluorescence (IF)
Frozen sections were dried, rehydrated in PBS, and preincubated with 1xPNB blocking 
buffer (Perkin Elmer). Sectioned were incubated overnight at 4°C with the following 
antibodies diluted in 1xPNB: CD31 (Dianova, DIA-310), Dll4 (R&D Systems, AF1389), 
and pIGFR Y116 (Abcam, ab39398), followed by 1-hour incubation at RT with Alexa dye-
tagged secondary antibodies (Life Technologies). DAPI (Invitrogen) was used to label the 
nuclei. Slides were mounted in ProLong Gold Mounting Medium (Invitrogen). Images were 
visualized under a Nikon microscope. Quantitation of lectin was performed using ImageJ.
Immunohistochemistry (IHC)
Mice were sacrificed by CO2 asphyxiation and lungs were inflated with 10% zinc formalin 
(Polysciences Inc.), fixed overnight in zinc formalin at RT, then transferred to 70% ethanol 
until paraffin embedding. IHC was performed on 5 μm thick sections using ABC Vectastain 
kit (Vector Labs) with antibodies to CD31 (Dianova, DIA-310), GFP (Cell signaling 2956), 
CD3 (Abcam, ab5690), B220 (Biolegend, 103202), MPO (Thermo Scientific, #RB-373-A0), 
IbaI (Wako), cleaved caspase 3 (Cell signaling 9661), KI67 (Vector Labs, VP-RM04) and 
SMA (Sigma Aldrich, A5228). The staining was visualized with DAB (Vector Labs, 
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SK-4100) and slides were counterstained with hematoxylin. For the apoptosis and 
proliferation analysis, quantitation was performed using ImageJ to determine the percentage 
of Ki67-positive cells and the number of cleaved caspase 3-positive cells per tumor area.
Luciferase assay
Full-length (5526 nt) or a shorter wild-type or mutant segment (1000 nt) of the 3′UTR of 
mouse Camk1d was cloned at the 3′ of Firefly luciferase in the pGL3-Promoter Luciferase 
Reporter Vector (Promega). Empty or 3′UTR-containing pGL3 were co-transfected with 
Renilla luciferase-expressing vector (pRL-TK, Promega) in MEFs using Attractene 
transfection reagent (Qiagen). Luciferase activity was assayed at 48 hours post transfection 
using Dual Luciferase Reporter Assay System (Promega). Firefly luciferase signal was 
normalized to Renilla luciferase signal.
RNA-seq analysis
Illumina HiSeq 2000 40-nt single-ended reads were mapped to the UCSC mm9 mouse 
genome. Independent Component Analysis (ICA), targeted pair-wise differential expression 
analysis, and gene set enrichment analysis (GSEA) were performed as described in (45). All 
primary RNA-seq data are available at Gene Expression Omnibus (GSE71877).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ABBREVIATIONS
miRNAs MicroRNAs
3′UTRs 3′ untranslated regions
K KrasLSL-G12D/+
KP KrasLSL-G12D/+; p53F/F
F floxed
- null
MEFs mouse embryonic fibroblasts
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qRT-PCR quantitative RT-PCR
t.v.i. tail vein injection
IHC immunohistochemistry
IF immunofluorescence
FISH fluorescence in situ hybridization
FACS fluorescence-activated cell sorting
ICA Independent Component Analysis
RNAseq RNA sequencing
HUVECs human umbilical vein endothelial cells
H&E hematoxylin and eosin
PFA paraformaldehyde
TRE tetracycline response element
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STATEMENT OF SIGNIFICANCE
This study shows that miR-143/145 expressed from the tumor microenvironment 
stimulates neoangiogenesis and supports tumor expansion in the lung, demonstrating a 
surprising role for the putative tumor suppressor miRNA cluster in promoting 
tumorigenesis. We propose inhibition of miR-143/145 as a therapeutic avenue to 
modulate tumor neoangiogenesis.
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Figure 1. Lack of cell-autonomous role for the miR-143/145 cluster in lung adenocarcinoma
(A, B) Taqman analysis of mature miR-143 expression in normal lung (N), (A) dissected 
KrasG12D/+ (K) and KrasG12D/+;p53−/− (KP) lung tumors or (B) cell lines derived from 
KrasG12D/+;p53−/− (KP) lung tumors. Data show mean±SEM.
(C) Schematic of the experimental design, showing the method for tumor initiation (t.i.) via 
intratracheal infection with adenoviral Cre recombinase (Adeno Cre).
(D) Quantification of the tumor burden of mice in (C). Mean and p-values using unpaired t-
test are indicated (n=2-5 mice).
(E) Survival curve of mice in (C) (n=4-9 mice).
(F) Schematic of the experimental design to test the effects of miR-143/145 overexpression.
(G) Fluorescence detection of mCherry and brightfield microscopy of lungs.
(H) qRT-PCR analysis of individual tumors dissected at 12 weeks post t.i.. Data show mean
±SEM of technical replicates.
(I) Quantification of tumor burden of mice in (F). Mean and p-values using unpaired t-test 
are indicated (n=3-4 mice).
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Figure 2. Stromal miR-143/145 promotes lung tumorigenesis
(A) (Left) Experimental setup. Color coded schematic of the status of the miR-143/145 locus 
in tumor cells vs lung stroma (miR-143/145+/+: red; miR-143/145−/−: blue). (Right) H&E 
staining of lung sections at 12 weeks post t.i..
(B-C) Quantification of (B) tumor area and (C) tumor number of experiment described in 
(A). Mean and p-values using unpaired t-test are indicated (n=7-8 mice).
(D) (Left) Experimental setup. Color coding as in (A). (Right) H&E staining of lung sections 
at 1 month post t.v.i.
(E) Quantification of tumor area of mice in (D). Mean and p-value using unpaired t-test are 
indicated (n=4-5 mice).
(F) IHC detection of EGFP-positive cells at indicated time-points post t.v.i. of mice in (D). 
Number of tumor nodules per section (n) and the number of EGFP-positive cells per tumor 
nodule are indicated.
(G) Fraction of Ki67-positive cells in lung tumors from mice in (D). Mean and p-value 
using unpaired t-test are indicated (n=10 tumors).
(H) Quantification of cleaved caspase 3 (CC3)-positive cells per tumor area of lung sections 
from mice in (D). Mean and p-value using unpaired t-test are indicated (n>35 tumors).
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Figure 3. Pattern of expression of the miR-143/145 cluster in normal and tumor-bearing lungs
(A) miRNA-FISH analysis of miR-145 expression pattern in normal (NL) or tumor-bearing 
lungs. DNA was counterstained with DAPI. No probe as negative control.
(B) Taqman analysis of mature miR-143 and miR-145 expression levels in sorted cell 
populations from K; miR-143/145+/+ lungs 16 weeks post t.i. Data show mean±SEM of 
technical replicates and were confirmed in a biological replicate.
(C) miRNA-FISH analysis of miR-145 and fluorescence detection of lectin in NL and 
tumor-bearing lungs in K; miR-143/145+/+ mice, sacrificed 16 weeks post t.i. DNA was 
counterstained with DAPI.
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Figure 4. Mitotic defect in miR-143/145-deficient tumor endothelium
(A) Schematic of the sorting strategy
(B) Unsupervised clustering of RNA-seq of samples in (A).
(C) Hinton plot of ICA of samples from (A). Columns represent the expression pattern of 
each signature. Red squares represent positive correlation and blue represents negative 
correlation with the signature; the size of the square reflects the degree of correlation. 
Statistically significant signature highlighted in bold.
(D) GSEA of the top 2%-ranked genes in Signature_End4 from (C) showing mitotic 
signature (FDR=0.0).
(E) Heatmap of relative expression of differentially expressed genes from pair-wise 
comparison; mitotic factors highlighted in blue.
(F) Normalized expression counts of three mitotic checkpoint components (MCC) Bub1, 
Cdc20, and Bub1b in experiment described in (A). Mean±SEM (n=3 mice) and p-values 
using Mann-Whitney test are shown.
(G) Immunoblot analysis of pHH3-Ser10 in whole cell lysates of CD31+ endothelial cells 
sorted from tumor-bearing lungs of indicated genotypes as described in (A). Lanes represent 
samples collected from independent animals. Hsp90 was used as a loading control.
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Figure 5. The miR-143/145 cluster promotes tumor neoangiogenesis
(A) CD31 IHC staining in lung tumors at 12 weeks post t.i. Arrows highlight honeycomb 
structures.
(B) Fluorescence detection of lectin in lung tumors at 12 weeks post t.i. DNA was 
counterstained with DAPI. Arrows highlight honeycomb structures.
(C) Quantification of lectin in samples from (B). Mean±SEM and p-value using unpaired t-
test are indicated.
(D) IF analysis of Dll4 staining and fluorescence detection of lectin in mice from (B). DNA 
was counterstained with DAPI. Arrows in merged images and enlarged panels indicate Dll4-
positive tip cells that are closely associated with the vasculature.
(E) Quantification of Dll4-positive cells of images in (D). Mean±SEM and p-value using 
unpaired t-test are indicated.
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Figure 6. Derepression of the miR-145 target, Camk1d, impairs angiogenesis
(A-B) CDF plots of (A) miR-143 and (B) miR-145 target expression fold change in 
miR-143/145-deficient endothelial cells relative to wild-type control in RNA-seq from Fig. 
4A.
(C) Venn diagram of the overlap of conserved miR-143 targets, conserved miR-145 targets, 
and genes, derepressed in miR-143/145−/− endothelial samples relative to miR-143/145+/+ 
controls (mean FC[KO/WT]>1.2). Only Camk1d showed significant differential expression 
(p<0.05). p-values determined using Krushal Wallis test.
(D) Normalized expression counts of Camk1d in RNA-seq of sorted CD31+ endothelial 
cells isolated from tumor-bearing mice in Fig. 4A. Data show mean±SEM (n=3 mice).
(E) Schematic of the sequence, evolutionary conservation, and mutational analysis of the 
two miR-145 target sites in the 3′UTR of Camk1d.
(F) Bar graph of luciferase reporter assay in miR-143/145-deficient cells relative to wild-
type controls transfected with no (−), short (1-1000 nt ) or long (full-length 1-5526) Camk1d 
3′UTR constructs.
(G) Bar graph of luciferase reporter assay in miR-143/145-proficient cells transfected with 
constructs expressing luciferase with no 3′UTR (−), wild-type Camk1d 3′UTR (+), mutant 
Camk1d 3′UTR at site 1 (mut1) or mutant 3′UTR at sites 1 and 2 (mut1+2).
(H) Immunoblot analysis of Camk1d and pHH3 levels in HUVECs, infected with empty 
vector (EV) or human Camk1d lentiviral construct. Non-specific band on the Camk1d 
immunoblot was used as a loading control.
Dimitrova et al. Page 22
Cancer Discov. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
(I) Brightfield microscopy at indicated time-points of tube formation assay with HUVECs 
infected with EV or human Camk1d lentiviral construct. Numbers indicate tubes per image 
field and show mean±SEM (n=5, unpaired t-test p=0.0059).
Dimitrova et al. Page 23
Cancer Discov. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
